

HISTORY

A 35 YEAR JOURNEY WITH A RELENTLESS FOCUS ON SCIENCE

Our commitment to patients extends well beyond our labs. We are proud to support the communities we serve, to embrace a culture and business model of patients over profits and to hold the highest ethical standards when it comes to patient well-being.

Jump to year: **2023**
 2022
 2021
 2020



Regeneron is founded by Leonard S. Schleifer, MD, PhD, a young neurologist and assistant professor at Cornell University Medical College

1988

- Len Schleifer describes how Regeneron raised its first \$1 million
- Len Schleifer explains how Regeneron got its name



George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron

1989

- Len and George reflect on their long partnership



Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

1990

We announce a collaboration to develop neurotrophic factors



REGN stock begins trading publicly on the NASDAQ; the initial public offering (IPO) raises \$91.6 million

1991



Clinical development of our first investigational drug, a neurotrophic

1992





Industry legend P. Roy Vagelos, MD becomes chairman of the board

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

1995



George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

1999



Our first paper on *VelociGene*[®] is published, introducing the world to our proprietary *Veloci* technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

2003



Sarilumab, our first fully human antibody, enters clinical development

A collaboration with Bayer HealthCare focuses on developing aflibercept outside the U.S.

2006



manufacturing facility in Rensselaer, NY, years before having an FDA-approved medicine



1997

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

2000

Our investigational medicine rilonacept begins clinical exploration



2004



Our investigational medicine aflibercept begins clinical development

2007

Y VELOCIMMUNE[®]

A collaboration with Sanofi focuses on developing fully human antibodies using our *Velocimmune*[®] technology platform

*In 2021, Kiniksa assumed U.S. commercial rights to ARCALYST for all approved indications



We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

2010



The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

2012



The Regeneron Genetics Center®, a new human genetics initiative, officially launches

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields. [Learn more about our initiatives](#)

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

2014



We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

2016

collaboration with Sanofi

Our investigational medicine alirocumab begins clinical development

2009

We hire our 1,000th employee and move into new buildings on our Tarrytown campus



2011

The FDA approves EYLEA® (afibercept) Injection for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

2013

Our European business office opens in Dublin, Ireland



Scrip Intelligence names Len and George as the "Management Team of the Year"



2015

The FDA approves PRALUENT® (alirocumab) Injection our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immunology collaboration with Sanofi



The FDA approves DUPIXENT® (dupilumab) Injection, our fifth FDA-approved medicine

2017





The FDA approves a new indication for [DUPIXENT® \(dupilumab\) Injection](#)

2018




The FDA approves [Libtayo® \(cemiplimab-rwlc\) Injection](#), our seventh FDA-approved medicine

approved medicine and second fully human monoclonal antibody

Recognized on the [Civic 50](#) list of most community-minded companies in the United States



The FDA approves an expanded indication for [DUPIXENT® \(dupilumab\) injection](#)



The FDA approves [Inmazoleb® \(atoltivimab, maftivimab, and odesivimab-ebgn\) Injection](#)

2020

Regeneron discovers and develops novel COVID-19 antibody cocktail in record time; FDA authorizes for emergency use

Regeneron named *Science* magazine's #1 biopharma company for the seventh time

2019



Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. Society for Science announces Regeneron as new sponsor of the International Science and Engineering Fair

The FDA and European Commission approves new indications for [EYLEA® \(afibercept\) injection](#), [DUPIXENT® \(dupilumab\) injection](#), [Libtayo® \(cemiplimab\) injection](#) and [PRALUENT® \(alirocumab\) injection](#)

Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies



The FDA and European Commission approve new indications for [DUPIXENT® \(dupilumab\) injection](#)



Regeneron takes full ownership of [Libtayo® \(cemiplimab\) injection](#), with exclusive worldwide development, commercialization and manufacturing rights

The FDA approved Libtayo in first-line NSCLC in combination with chemotherapy in the fourth quarter of 2022

2022

2021

The FDA approves new indications for [Libtayo® \(cemiplimab-rwlc\) injection](#) and [DUPIXENT® \(dupilumab\) injection](#); European Commission approves a new indication for [Libtayo® \(cemiplimab\) injection](#)

The European Commission authorizes Regeneron's COVID-19 antibody cocktail

Regeneron and Intellia announce first-ever clinical data supporting the safety and efficacy of *in vivo* CRISPR genome editing




[Regeneron Genetics Center](#) discovers *GPR75* gene mutations that protect against obesity



Regeneron acquires Checkmate





Inmazole

(atolivimab, maffivimab,
and odesivimab - ebgn)
Injection

Regeneron awarded the [2022 Prix Galien USA Best Biotechnology Product for Inmazole](#)

M.D. retires as board chair

Drs. Leonard S. Schleifer and George D. Yancopoulos become co-chairs of the board

2023



The FDA approves [Veopoz](#)™ (pozelimab-bbfg), our tenth FDA-approved medicine



The FDA approves [EYLEA](#)® HD (aflibercept) Injection 8 mg, our eleventh FDA-approved medicine



There may be no other thing you can do that is more rewarding than to really move the human condition forward

George D. Yancopoulos, MD, PhD

Board Co-Chair, President and Chief Scientific Officer

REGENERON
SCIENCE TO MEDICINE™



[Terms of Use](#) >

[Social Media Terms of Engagement](#) >

[Site Map](#) >

[Privacy Notice](#) >

[Cookie Policy](#) >

[Privacy Preference Center](#) >

[Accessibility Statement](#) >

[OUR LOCATIONS](#) >

[INVESTORS & MEDIA](#) >

[CAREERS](#) >

[CLINICAL TRIALS](#) >

Copyright © 2024 Regeneron Pharmaceuticals Inc. All rights reserved. All trademarks mentioned are the property of their respective owners.

The information provided on this website is for U.S. residents only.

BACK TO TOP